Home
>
Section
>
Chapter
Chedraui, P.; Perez-Lopez, F.R.
International Society of Gynecological Endocrinology Series: 179-189
2021
ISSN/ISBN: 2197-8735 Accession:098487598Full-Text Article emailed within 1 workday
Payments are secure & encrypted
Summary
The polycystic ovary syndrome (PCOS) is the most prevalent female endocrine disorder in which hyperandrogenism is the main clinical feature. These steroids contribute to excessive weight gain, insulin resistance, hirsutism, acne, and androgenic alopecia. Visceral fat hypertrophy and androgen excess correlates with the degree of insulin resistance, the worse PCOS phenotype, and cardiovascular risk factors. Abnormal secretion of many adipocyte-derived products will produce a state of chronic low-intensity inflammation that progressively affects every organ and system. Appropriate nutrition, physical activity, and exercise may improve body composition, and metabolic and endocrine functioning. Different supplements (minerals, vitamins, and probiotics) may also contribute to neutralize the evolution of the syndrome.References
Clark, N.M.; Podolski, A.J.; Brooks, E.D.; Chizen, D.R.; Pierson, R.A.; Lehotay, D.C.; Lujan, M.E. 2014: Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome Reproductive Sciences 21(8): 1034-1043
Christ, J.P.; Gunning, M.N.; Fauser, B.C.J.M. 2017: Implications of the 2014 Androgen Excess and Polycystic Ovary Syndrome Society guidelines on polycystic ovarian morphology for polycystic ovary syndrome diagnosis Reproductive Biomedicine Online 35(4): 480-483
Bulut, G.; Kurdoglu, Z.; Dönmez, Y.B.; Kurdoglu, M.; Erten, R. 2015: Effects of jnk inhibitor on inflammation and fibrosis in the ovary tissue of a rat model of polycystic ovary syndrome International Journal of Clinical and Experimental Pathology 8(8): 8774-8785
Liu, M.; Guo, S.; Li, X.; Tian, Y.; Yu, Y.; Tang, L.; Sun, Q.; Zhang, T.; Fan, M.; Zhang, L.; Xu, Y.; An, J.; Gao, X.; Han, L.; Zhang, L. 2024: Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice Drug Design Development and Therapy 18: 3925-3938
Prabhu, Y.D.; Borthakur, A.; A G, S.; Vellingiri, B.; Valsala Gopalakrishnan, A. 2021: Increased pro-inflammatory cytokines in ovary and effect of γ-linolenic acid on adipose tissue inflammation in a polycystic ovary syndrome model Journal of Reproductive Immunology 146: 103345
Cankaya, S.; Demir, B.; Aksakal, S.E.; Dilbaz, B.; Demirtas, C.; Goktolga, U. 2014: Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome Fertility and Sterility 102(3): 826-830
Ganie, M.A.; Hassan, S.; Nisar, S.; Shamas, N.; Rashid, A.; Ahmed, I.; Douhat, S.; Mudassar, S.; Jan, V.M.; Rashid, F. 2014: High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS) Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 30(11): 781-784
Myers, E.R.; Silva, S.G.; Hafley, G.; Kunselman, A.R.; Nestler, J.E.; Legro, R.S. 2005: Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial Contemporary Clinical Trials 26(3): 271-280
Mrozińska, S.; Milewicz, T.; Kiałka, M.; Gosztyła, K.; Lurzyńska, Młgorzata.; Kabzińska-Turek, M. 2016: There is no difference in the plasma cortisol level between women with body mass index (BMI) greater than or equal 25 kg/m² and polycystic ovary syndrome and the control group without polycystic ovary syndrome and BMI 25 kg/m² Przeglad lekarski 73(4): 207-209
Coffey, S.; Bano, G.; Mason, H.D. 2006: Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36) Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 22(2): 80-86
Cataldo, N.; Legro, R.; Myers, E.; Barnhart, H. 2007: Co-treatment with metformin XR does not reduce the threshold dose of clomiphene to induce ovulation in polycystic ovary syndrome: results from the pregnancy in polycystic ovary syndrome (PPCOS) study Fertility and Sterility 88: S73-S74
Stadtmauer, L.A.; Wong, B.C.; Oehninger, S. 2002: Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction Human Reproduction 17(12): 3016-3026
Kaya, C.; Erkan, A.F.; Cengiz, S.D.çe.; Dünder, I.; Demirel, Öz.E.ş; Bilgihan, A.şe. 2009: Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome Fertility and Sterility 92(4): 1372-1377
Gairola, N.; Chitme, H.R.; Sircar, R. 2024: Systemic effects of clinical follicular fluid from polycystic ovary syndrome and non-polycystic ovary syndrome in female mice Indian Journal of Experimental Biology 62(3): 169-178
Schuring, A.N.; Schulte, N.; Sonntag, B.; Kiesel, L. 2008: Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome Gynakologisch-Geburtshilfliche Rundschau 48(1): 9-15
Ganie, M.A.; Rashid, A.; Baba, M.S.; Zargar, M.A.; Wani, I.A.; Nisar, S.; Wani, I.A.; Douhath, S.; Sriwastawa, M.; Geer, M.I.; Asrar, M.M.; Kutum, R.; Hassan, S.; Khan, S.; Rafi, W.; Bhat, D.A.; Showkat, W.; Sahar, T.; Choh, N.A.; Khurshid, R.; Mudassar, S.; Shah, Z.A.; Shabir, I.; Sofi, S.A.; Gupta, N.; Hafeez, I.; Sreenivas, V. 2023: Pre-polycystic ovary syndrome and polymenorrhoea as new facets of polycystic ovary syndrome (PCOS): Evidences from a single centre data set Clinical Endocrinology 99(6): 566-578
Halasawadekar, N.; Ramanand, J.; Ramanand, S.; Raparti, G.; Patil, P.; Shah, R.; Kumbhar, A. 2016: Serum lipid profile in non-polycystic ovary syndrome and polycystic ovary syndrome women: a comparative and correlational study International Journal of Basic and Clinical Pharmacology: 105-111
Moran, L.J.; Pasquali, R.; Teede, H.J.; Hoeger, K.M.; Norman, R.J. 2009: Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society Fertility and sterility 92(6): 1966-1982
Khattak, M.; Usman, R.; Sultana, N.; Khattak, A. 2021: Comparison of Free Androgen Index in Polycystic Ovary Syndrome and Non-Polycystic Ovary Syndrome Infertile Patients Journal of Ayub Medical College Abbottabad: Jamc 33(4): 577-581
Tasci, I.; Naharci, M.I. 2020: Metabolomics and inflammation in polycystic ovary syndrome Journal of Endocrinological Investigation 43(8): 1165
